ライフサイエンスコーパス: antibacterial agent

1 ons of materials impregnated with a leaching antibacterial agent.

2 s used, suggesting that it can be used as an antibacterial agent.

3 ocarban and triclosan, another commonly used antibacterial agent.

4 lidixic acid (NAL), a recalcitrant quinolone antibacterial agent.

5 s the potential to be developed into a novel antibacterial agent.

6 indicating its potential applications as an antibacterial agent.

7 tics as well as a lack of development of new antibacterial agents.

8 ew target are not cross-resistant with other antibacterial agents.

9 help to fill the growing unmet need for new antibacterial agents.

10 ch attention as a potential target for novel antibacterial agents.

11 inhibitors for HMM PBPs as HMM PBP targeted antibacterial agents.

12 e biochemical tools and attractive potential antibacterial agents.

13 se is an attractive target for the design of antibacterial agents.

14 in directly assessing D-Ala branch targeted antibacterial agents.

15 xicity, KdsC is a potential target for novel antibacterial agents.

16 hat Gcp may be a novel target for developing antibacterial agents.

17 nexploited target for the development of new antibacterial agents.

18 iotics demonstrates the medical need for new antibacterial agents.

19 unnatural oligomers intended to function as antibacterial agents.

20 nones represent a new and promising class of antibacterial agents.

21 s of the MazEF interaction have potential as antibacterial agents.

22 thus an attractive target for developing new antibacterial agents.

23 lopyridones and their in vitro evaluation as antibacterial agents.

24 g to the use of purified phage components as antibacterial agents.

25 targets for the discovery and development of antibacterial agents.

26 ion and potentially provide a novel class of antibacterial agents.

27 ides a paradigm shift towards development of antibacterial agents.

28 or antibiotic discovery and developing novel antibacterial agents.

29 ttractive targets for the development of new antibacterial agents.

30 nones represent a new and promising class of antibacterial agents.

31 otential target for the development of novel antibacterial agents.

32 r developing highly specific and efficacious antibacterial agents.

33 plex should be candidates as leads for novel antibacterial agents.

34 n and suggest strategies for design of novel antibacterial agents.

35 r developing highly specific and efficacious antibacterial agents.

36 ds for the development of new broad-spectrum antibacterial agents.

37 fflux pump AcrAB-TolC expels a wide range of antibacterial agents.

38 ginosa-specific quorum-sensing inhibitors as antibacterial agents.

39 genesis and opens a new venue for developing antibacterial agents.

40 droxyethyl)pyrrolidine-2,4-dione, are potent antibacterial agents.

41 herefore represents an attractive target for antibacterial agents.

42 a potential target for development of novel antibacterial agents.

43 were inactive as either enzyme inhibitors or antibacterial agents.

44 tudies on NAD synthetase as a new target for antibacterial agents.

45 rganisms in order to preserve the utility of antibacterial agents.

46 tractive target for the development of novel antibacterial agents.

47 l enoyl-ACP reductases are valid targets for antibacterial agents.

48 tentially viable strategy for developing new antibacterial agents.

49 d perhaps even to develop novel FHA-blocking antibacterial agents.

50 asis for the development of new PBP-targeted antibacterial agents.

51 attractive target for the development of new antibacterial agents.

52 get ribosomal RNA and uncover a new class of antibacterial agents.

53 to be valuable targets for identifying novel antibacterial agents.

54 nce in patients with type II diabetes and as antibacterial agents.

55 utilized for the identification of potential antibacterial agents.

56 received considerable interest as potential antibacterial agents.

57 h the bacterial toxin CcdB and the quinolone antibacterial agents.

58 riophages to increase their effectiveness as antibacterial agents.

59 ent the first examples of H. pylori-specific antibacterial agents.

60 specific deformylase inhibitors as potential antibacterial agents.

61 recipients should include antifungal and not antibacterial agents.

62 ntriguing targets for the development of new antibacterial agents.

63 ch can be optimized to design more selective antibacterial agents.

64 tial in prokaryotes, it is a good target for antibacterial agents.

65 ys should guide designs of new mineral-based antibacterial agents.

66 eloping phage into therapeutically effective antibacterial agents.

67 dylate synthase (TS) and as antitumor and/or antibacterial agents.

68 discovery and development efforts toward new antibacterial agents.

69 ides (AMPs) should help in the design of new antibacterial agents.

70 n mechanism and discovery of target-specific antibacterial agents.

71 argets for the design and development of new antibacterial agents.

72 ell as identifying candidate targets for new antibacterial agents.

73 tanding of the development of broad-spectrum antibacterial agents.

74 y is one of the most important properties of antibacterial agents.

75 is challenge will require development of new antibacterial agents.

76 idated for the evaluation of the efficacy of antibacterial agents.

77 suitable platform for future development of antibacterial agents.

78 biotic overuse compel us to seek alternative antibacterial agents.

79 as promising candidates in the market as new antibacterial agents.

80 traits, such as virulence and resistance to antibacterial agents.

81 actams, 10 on glycopeptides, and 12 on other antibacterial agents.

82 er development of this class of compounds as antibacterial agents.

83 in particular is a well-validated target for antibacterial agents.

84 s of the LPS and their role in resistance to antibacterial agents.

85 of action could be exploited to develop new antibacterial agents.

86 al ribosome makes it an important target for antibacterial agents.

87 ultimately approval of critically needed new antibacterial agents.

88 ction models that was comparable to marketed antibacterial agents.

89 ultimately approval of critically needed new antibacterial agents.

90 attractive target for the development of new antibacterial agents.

91 , and their biosynthesis is a target for new antibacterial agents.

92 Bacterial methylation of an antibacterial agent, 14, catalyzed by Rv0560c of Mtb, is

93 aluation of a new generation of tetracycline antibacterial agents, 7-fluoro-9-substituted-6-demethyl-

94 creases resistance to two positively charged antibacterial agents, a beta-lactam and high concentrati

95 xazolidinones are a novel class of synthetic antibacterial agents active against gram-positive organi

96 se with the potential to be novel and potent antibacterial agents active against pathogenic bacteria.

97 The role of prophylactic antibacterial agents after chemotherapy remains controve

98 similar potency to the natural product as an antibacterial agent against a variety of strains, includ

99 s that TA is the major M. xanthus-diffusible antibacterial agent against E. coli.

100 tructure-based drug design of a new class of antibacterial agents against a clinically proven, but co

101 vitro activity of ceftaroline and comparator antibacterial agents against ABSSSI and CABP pathogens.

102 rategy that enables the development of novel antibacterial agents against clinically relevant Gram-ne

103 and 3 warrant further investigation as novel antibacterial agents against drug-resistant enterococci.

104 These compounds were found to be potent antibacterial agents against Gram-positive organisms in

105 vitro activity of ceftaroline and comparator antibacterial agents against invasive respiratory isolat

106 (MenA) inhibitors 1a and 2a act as selective antibacterial agents against organisms such as methicill

107 lop selective class II inhibitors for use as antibacterial agents against pathogenic microorganisms.

108 fore, identifying an effective antibiotic or antibacterial agent and administering it at concentratio

109 should be informative in the search for new antibacterial agents and drug targets.

110 splays little cross-resistance with marketed antibacterial agents and is active against methicillin-r

111 l wall biosynthesis is the target of several antibacterial agents and is also of interest as a target

112 selves in a continual battle to identify new antibacterial agents and targets.

113 ween the physicochemical properties of known antibacterial agents and the HTS active starting point,

114 , which had not previously been evaluated as antibacterial agents and were found to be potent inhibit

115 sisting of sulfapyridine, a sulfa-containing antibacterial agent, and 5-amino-salicylate (5-ASA), an

116 ple organ failure, exposed to broad-spectrum antibacterial agents, and enrolled between July 2012 and

117 gnostic studies, decreasing empirical use of antibacterial agents, and facilitating early identificat

118 is a problem that is often encountered with antibacterial agents, and it is also an issue with antif

119 arget for reversal of resistance to selected antibacterial agents, and recently we described indole-b

120 rapeutic target for the development of novel antibacterial agents, and we continue to explore TMK inh

121 Several new antibacterial agents are currently being developed in re

122 At least 18 antibacterial agents are currently undergoing clinical t

123 A number of new antibacterial agents are in late stage clinical developm

124 ces from the human FAS, and several existing antibacterial agents are known to inhibit FASII enzymes.

125 Silver nanoparticles (AgNPs), an effective antibacterial agent, are a significant and fast-growing

126 e of our investigations in the oxazolidinone antibacterial agent area, we have identified a subclass

127 for further development of borinic esters as antibacterial agents as well as leads to explore more sp

128 identified actinonin, a naturally occurring antibacterial agent, as a potent PDF inhibitor.

129 Among the targets for the development of new antibacterial agents, bacterial topoisomerases remain a

130 Novel quinolone antibacterial agents bearing (3S)-amino-(4R)-ethylpiperi

131 Fluoroquinolones are potent antibacterial agents being used clinically against multi

132 tical not only in designing newer-generation antibacterial agents but also in providing insight into

133 in the development and marketing of over 100 antibacterial agents but, with the exception of the oxaz

134 s) are widely used in commercial products as antibacterial agents, but AgNPs might be hazardous to th

135 protein, Siderocalin (Scn), which acts as an antibacterial agent by specifically sequestering siderop

136 san (LMWC) and nisin, recognized as cationic antibacterial agents (CAAs), inhibit bacterial growth by

137 Antibiotic resistance and the lack of new antibacterial agents cause major challenges for the trea

138 such as the natural product nitrofungin, the antibacterial agent chloroxylenol, and the herbicide chl

139 ions that confer resistance to the quinolone antibacterial agents cluster at the new dimer interface,

140 A new and promising group of antibacterial agents, collectively known as the oxazolid

141 nto target-based approaches to produce novel antibacterial agents, companies large and small have exi

142 nd libraries led to the discovery of a novel antibacterial agent, compound 1 (MIC: 12-25 microM again

143 ew target is different from targets of other antibacterial agents, compounds that bind to the new tar

144 Several other classes of antibacterial agents currently in clinical trials are re

145 d is also of interest as a target for future antibacterial agent development.

146 oA reductases thus are potential targets for antibacterial agents directed against multidrug-resistan

147 and for the discovery and development of new antibacterial agents directed toward novel targets.

148 in the analytical methodology available for antibacterial agent discovery and characterization.

149 otential target for the development of novel antibacterial agents due to its unique physiological and

150 the biosynthetic pathway for the widely used antibacterial agent erythromycin.

151 y of gepotidacin, a new triazaacenaphthylene antibacterial agent for the treatment of conventional an

152 s inhibitors of NAD synthetase and as potent antibacterial agents for Gram-positive strains.

153 ic analogues have been among the most useful antibacterial agents for the treatment of infectious dis

154 vice database were analyzed, with a focus on antibacterial agents from 2001 to 2013.

155 osed to a subinhibitory concentration of the antibacterial agent, glyphosate.

156 This parenteral antibacterial agent has a dual mechanism of action and p

157 Target-based screening for new antibacterial agents has been particularly disappointing

158 en-carbon-linked (azolylphenyl)oxazolidinone antibacterial agents has been prepared in an effort to e

159 bined with the decline in discovery of novel antibacterial agents has created a global public health

160 enzymes by actinonin, a naturally occurring antibacterial agent, has been characterized using steady

161 Antibacterial agents have been historically studied in n

162 Several antibacterial agents have been studied as a means to pro

163 Traditionally, antibacterial agents have been studied in noninferiority

164 ones are a relatively new class of synthetic antibacterial agents, having a new mechanism of action w

165 The pathogen, with its susceptibility to an antibacterial agent (ie, pharmacodynamics [PD]), is a gi

166 cture of a potent, new class, broad-spectrum antibacterial agent in complex with Staphylococcus aureu

167 Triclocarban is widely used as an antibacterial agent in personal care products, and the p

168 iology, suggest that phages may be useful as antibacterial agents in certain conditions.

169 tribute to the fate and transport of OA-type antibacterial agents in marine sediments and waters.

170 elationships have been found among macrolide antibacterial agents in their potencies against the bact

171 3-anhydro macrolides were found to be potent antibacterial agents in vitro against macrolide-suscepti

172 The bacillus is susceptible to several antibacterial agents in vitro, including penicillins, ce

173 romised the effectiveness of most classes of antibacterial agent, including the classes that target t

174 ibe studies leading to the identification of antibacterial agents incorporating a novel isoxazoline A

175 Rifamycin antibacterial agents inhibit bacterial RNA polymerase (R

176 he primary target for the quinolone group of antibacterial agents is DNA gyrase.

177 ns, and resistance to virtually all approved antibacterial agents is emerging in this pathogen.

178 novative combination approaches and/or novel antibacterial agents is occurring in the context of redu

179 this problem is encountered more often with antibacterial agents, it is also an issue with antifunga

180 ontinue to be actively developed as clinical antibacterial agents, largely owing to the success of th

181 olide, and nonylphenol are representative of antibacterial agents, nitro-musks, and surfactants, resp

182 It is disturbing that the antibacterial agents of the most advanced type, which ar

183 Natural and synthetic membrane active antibacterial agents offer hope as potential solutions t

184 Their development as novel antibacterial agents offers many potential advantages ov

185 No inhibition by antibacterial agents or disinfectants from the hospital

186 the small-molecule cell-cycle inhibitor and antibacterial agent PC190723 that targets FtsZ.

187 The successful preparation of an antibacterial agent precursor was also investigated.

188 Microcin C (McC) is a potent antibacterial agent produced by some strains of Escheric

189 Unlike most antibacterial agents, PZA, despite its remarkable in viv

190 From a public health perspective, new antibacterial agents should be evaluated and approved fo

191 upported effort, yielding a unique series of antibacterial agents showing a novel, induced-fit bindin

192 lyfunctional amines has led to new macrolide antibacterial agents, some of which are highly potent ag

193 noquinzolinediones represent a new series of antibacterial agents structurally related to the fluoroq

194 Dental composites releasing antibacterial agents such as chlorhexidine (CHX) have sh

195 Quinolones linked to other antibacterial agents such as rifamycins and oxazolidinon

196 cent increase in research into orally active antibacterial agents, such as carbapenems and cephalospo

197 Various antitumor and antibacterial agents target type II DNA topoisomerases,

198 ETX0914, the first of a new class of antibacterial agent targeted for the treatment of gonorr

199 all aminoglycoside neamine as broad spectrum antibacterial agents targeting bacterial membranes.

200 here should be useful for the development of antibacterial agents targeting TMK without undesired off

201 mbda mutants also have greater capability as antibacterial agents than the corresponding parental str

202 er, and yet equipotent, or even more potent, antibacterial agents than the natural product, thereby s

203 AZD5099 (compound 63) is an antibacterial agent that entered phase 1 clinical trials

204 Triclosan is a broad-spectrum antibacterial agent that inhibits bacterial fatty acid s

205 Ceftaroline is a new antibacterial agent that is active against the major bac

206 first member of a promising, novel class of antibacterial agents that act by inhibiting bacterial DN

207 or testing the susceptibility of bacteria to antibacterial agents that affect their cell wall.

208 inones are a new chemical class of synthetic antibacterial agents that are active orally or intraveno

209 e are of interest for the development of new antibacterial agents that are impacted by target-mediate

210 y applied to the discovery of in vivo active antibacterial agents that are inhibitors of bacterial pe

211 ) are of interest for the development of new antibacterial agents that are not impacted by target-med

212 Fluoroquinolones are antibacterial agents that attack DNA gyrase and topoisom

213 ry bacterium, making it a logical target for antibacterial agents that can convert the enzyme into po

214 this end, present feasible trial designs for antibacterial agents that could enable conduct of narrow

215 e sought to define feasible trial designs of antibacterial agents that could enable conduct of superi

216 eptide (ADEP) antibiotics are a new class of antibacterial agents that kill bacteria via a mechanism

217 benzisoxazole ring represent a new class of antibacterial agents that operate by inhibition of DNA g

218 ngs provide scope for the development of new antibacterial agents that prevent DAPDC dimerization.

219 Quinolones are potent antibacterial agents that specifically target bacterial

220 ound approaches (products other than classic antibacterial agents) that target bacteria or any approa

221 e is the target for the diazaborine class of antibacterial agents, the biocide triclosan, and one of

222 Despite treatment with antifungal and antibacterial agents, the patient developed progressive

223 ready been established as a target for novel antibacterial agents through suicide inactivation by a n

224 tion of repurposing simvastatin as a topical antibacterial agent to treat skin infections.

225 The development of new antibacterial agents to combat worsening antibiotic resi

226 nones represent the first truly new class of antibacterial agents to reach the marketplace in several

227 New antibacterial agents to treat infections caused by antib

228 a critical need for new pathways to develop antibacterial agents to treat life-threatening infection

229 rsists for new, feasible pathways to develop antibacterial agents to treat people infected with drug-

230 y prevalence in children and exposure to the antibacterial agent triclosan and having filaggrin (FLG)

231 enzyme for folate antagonists, including the antibacterial agent trimethoprim (TMP).

232 an R-plasmid, that confers resistance to the antibacterial agent trimethoprim.

233 ng the benefits and harms of a controversial antibacterial agent undergo change when passed from one

234 The therapeutic application of phages as antibacterial agents was impeded by several factors: (i)

235 biotics including antiviral, antifungal, and antibacterial agents were administered during the treatm

236 s largely based on retrospective analyses of antibacterial agents, which suggest that polarity and mo

237 otoswitchable antibiotics, we introduce here antibacterial agents whose activity can be controlled by

238 ective control of cytokine concentrations by antibacterial agents will clearly have important therape

239 f biological activity surfacing as an active antibacterial agent with an intriguing mode of action.

240 se synergistic roles for human SPLUNC1 as an antibacterial agent with bacteriostatic and chemotactic

241 een used clinically, although it is a potent antibacterial agent with low toxicity (Therapeutic Index

242 In order to develop a potent antibacterial agent with the desired spectrum of activit

243 te model should facilitate the design of new antibacterial agents with improved activity against S. p

244 The discovery of new antibacterial agents with novel mechanisms of action is

245 d enabling their discovery as broad-spectrum antibacterial agents, with promising activity against bo